4SC develops orally available small molecule drugs for the treatment of cancer and autoimmune diseases focusing on epigenetic targets.
Wellington contact: Rainer Strohmenger
Actelion went public on the Swiss Stock Exchange in 2000. Today it has a market cap of more than CHF17B.
Atopix was acquired by Chiesi Farmaceutici in 2016 for more than €75M.
Location: United Kingdom
Wellington contact: Regina Hodits
Ayoxxa markets its innovative, patented beads-on-a-chip technology (LUNARIS™) to analyze multiple biomarkers in very low volume biological samples.
Definiens was acquired by MedImmune in 2015 for US$150M plus earnouts.
EndoStim is marketing a device for the treatment of Gastro-esophageal Reflux Disease (GERD), commonly known as acid reflux, via electrical stimulation of the lower esophageal sphincter.
Evolva (SWX: EVE) is focused on discovering, producing and supplying innovative, sustainable ingredients for health, wellness and nutrition.
Wellington contact: Erich Schlick
G-Therapeutics is developing an implantable stimulation system and a robot-assisted training program to rehabilitate individuals with spinal cord injury.
Genkyotex (EPA: GKTX) is developing first-in-class selective inhibitors of NOX enzymes for an orphan fibrotic disease as well as for angiogenesis, pain and inflammation.
Grandis was acquired in 2000 by Novartis.
ImevaX develops a novel therapeutic vaccine for treatment of Helicobacter pylori, the cause of gastric cancer, by targeting essential bacterial immune evasion factors.
Immatics is developing Adoptive Cell Therapy (ACT) and soluble T cell receptor (sTCR) approaches based on the company's unrivalled XPRESIDENT cancer target discovery platform.
Implanet specializes in development and commercialization of proprietary orthopedic implants with a focus on spine (JAZZ platform) and knee.
invendo medical is a leading developer and vendor of sterile, single-use and light-weight robotically-assisted HD endoscopy products in the field of gastroenterology and GI interventions.
iOmx is a next-generation immuno-oncology company focused on novel pathways for T cell evasion by cancer.
Middle Peak Medical is developing new minimally invasive, catheter-based treatment options for mitral valve disease. It was acquired by Symetis in 2017.
mtm labs was acquired by Roche in 2011 for up to US$273M.
NEUWAY Pharma is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform.
NoemaLife went public on Borsa Italiana in 2006.
Oxford Immunotec (NASDAQ: OXFD) focuses on developing and commercializing proprietary tests for latent tuberculosis and management of immune-regulated conditions.
Quanta is developing and marketing easy-to-use and portable haemodialysis systems with full clinical performance for use in the home and clinic.
Rigontec is developing a RIG-I agonist platform that harnesses one of the most essential pathways in the innate immune system to pioneer novel immuno-oncology treatments.
Sapiens was acquired by Medtronic in 2014 for US$200M.
Sensimed has developed a digital contact lens with telemetry features - the Triggerfish® - that provides automated 24h recording of continuous ocular dimensional / intraocular pressure changes for Glaucoma management.
SuperSonic Imagine (EPA:SSI) markets a unique imaging system combining shear wave elastography with conventional ultrasound, a new method to visualize soft tissues and diffentiate malignant from normal tissues at early tumor stages.
Symetis is the leading 2nd generation provider of innovative, minimally invasive heart valve replacement devices and is marketing its products, ACURATE TA™ and ACURATE neo™ in the constantly growing TAVI market.
Technolas Perfect Vision was acquired by Bausch & Lomb in 2013 for more than US$400M.
Wellington contact: Rainer Stromenger
Themis is developing vaccines to prevent infectious diseases based on its Themaxyn™ platform with an emphasis on emerging tropical diseases and large unmet need indications.
Uromems is developing an active implantable medical device for treating male and female stress urinary incontinence.
Wavelight went public on the Frankfurt Stock Exchange in 1999 and was acquired by Alcon in 2007 for more than US$90M.